/RPRX
RPRX Stock - Royalty Pharma plc
Healthcare|BiotechnologyNASDAQ
$38.60+0.44%
+$0.17 (+0.44%) • Dec 19
72
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.64
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).75
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+12.7%upside
Target: $43.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RPRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$38.21 – $38.99
TARGET (TP)$43.50
STOP LOSS$35.51
RISK/REWARD1:1.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.46
52W High$41.24
52W Low$24.46
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.26B | $2.35B | $2.24B | $2.29B | $2.12B |
| Gross Profit | $2.26B | $2.35B | $2.24B | $2.29B | $1.89B |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 89.1% |
| Operating Income | $1.29B | $1.49B | $307.06M | $1.43B | $1.60B |
| Net Income | $858.98M | $1.13B | $42.83M | $619.73M | $975.04M |
| Net Margin | 37.9% | 48.2% | 1.9% | 27.1% | 45.9% |
| EPS | $1.92 | $2.54 | $0.10 | $1.49 | $2.51 |
Company Overview
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
80%
Hold / Neutral
1
20%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
4 Bullish1 Neutral/Bearish
Price Targets
$47
Average Target
↑ 21.0% Upside
Now
$28
Low
$47
Average
$56
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 30th 2025 | Goldman | Initiation | Buy | $42 |
| May 16th 2025 | Morgan Stanley | Initiation | Overweight | $51 |
| June 3rd 2024 | UBS | Downgrade | Neutral | $28 |
| June 14th 2022 | UBS | Resumed | Buy | $47 |
| May 13th 2022 | Scotiabank | Initiation | Sector Outperform | $53 |
| April 27th 2022 | Goldman | Initiation | Buy | $56 |
| April 14th 2022 | JP Morgan | Upgrade | Overweight | $50 |
Earnings History & Surprises
RPRXBeat Rate
72%
Last 18 quarters
Avg Surprise
+5.5%
EPS vs Estimate
Beats / Misses
13/4
1 met exactly
Latest EPS
$1.17
Q4 2025
EPS Surprise History
Q1 24
+13.9%
$1.15vs$1.01
Q2 24
-0.7%
$0.98vs$0.99
Q3 24
-0.5%
$0.96vs$0.96
Q4 24
+12.1%
$1.04vs$0.93
Q1 25
+16.2%
$1.15vs$0.99
Q2 25
+11.2%
$1.06vs$0.95
Q3 25
+10.7%
$1.14vs$1.03
Q4 25
+17.7%
$1.17vs$0.99
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 10, 2026 | $1.28 | — | — | — |
Q4 2025 | Nov 5, 2025 | $0.99 | $1.17 | +17.7% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $1.03 | $1.14 | +10.7% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $0.95 | $1.06 | +11.2% | ✓ BEAT |
Q1 2025 | Feb 11, 2025 | $0.99 | $1.15 | +16.2% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $0.93 | $1.04 | +12.1% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $0.96 | $0.96 | -0.5% | ✗ MISS |
Q2 2024 | May 9, 2024 | $0.99 | $0.98 | -0.7% | ✗ MISS |
Q1 2024 | Feb 15, 2024 | $1.01 | $1.15 | +13.9% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $0.81 | $0.79 | -2.5% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $0.83 | $0.85 | +2.4% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $1.32 | $1.60 | +21.2% | ✓ BEAT |
Q1 2023 | Feb 15, 2023 | $1.56 | $1.56 | 0.0% | = MET |
Q4 2022 | Nov 8, 2022 | $0.71 | $0.73 | +2.8% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $0.78 | $0.79 | +1.3% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $0.72 | $0.61 | -15.3% | ✗ MISS |
Q1 2022 | Feb 15, 2022 | $0.79 | $0.80 | +1.3% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $0.69 | $0.73 | +5.8% | ✓ BEAT |
Q3 2021 | Aug 11, 2021 | $0.70 | $0.71 | +1.4% | ✓ BEAT |
Latest News
Royalty Pharma Acquires Pre-Existing Royalty Interest In Nuvalent's Neladalkib And Zidesamtinib From Undisclosed Third Party For Up To $315M
📈 PositiveBenzinga•Dec 16, 2025, 12:16 PM•Also:
TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $45
📈 PositiveBenzinga•Dec 11, 2025, 04:29 PM
Denali Therapeutics shares are trading higher after the company and Royalty Pharma announced a $275 million synthetic royalty funding agreement.
📈 PositiveBenzinga•Dec 4, 2025, 06:14 PM•Also:
Denali Therapeutics And Royalty Pharma Announce $275M Synthetic Royalty Funding Agreement Based On Future Net Sales Of Tividenofusp Alfa
📈 PositiveBenzinga•Dec 4, 2025, 12:05 PM•Also:
Royalty Pharma Q3 Adj. EPS $1.17 Beats $1.04 Estimate, Sales $609.000M Miss $739.257M Estimate
➖ NeutralBenzinga•Nov 5, 2025, 12:03 PM
Royalty Pharma acquires royalty interest in Alnylam's AMVUTTRA for $310M
📈 PositiveSeeking Alpha•Nov 4, 2025, 01:40 PM•Also:
Royalty Pharma Acquires Royalty Interest In Alnylam's Amvuttra From Blackstone Life Sciences For $310M
📈 PositiveBenzinga•Nov 4, 2025, 12:18 PM•Also: ,
Morgan Stanley Maintains Overweight on Royalty Pharma, Lowers Price Target to $54
➖ NeutralBenzinga•Oct 10, 2025, 05:40 PM
Goldman Sachs Initiates Coverage On Royalty Pharma with Buy Rating, Announces Price Target of $42
📈 PositiveBenzinga•Sep 30, 2025, 01:03 PM
Royalty Pharma Guides For $4.7B Portfolio Receipts And $4B Cash Flow By 2030, Exceeding Analyst Estimates
📈 PositiveBenzinga•Sep 11, 2025, 11:03 AM
Reported Earlier, Royalty Pharma Prices $2B Senior Unsecured Notes Offering With $600M Due 2031 At 4.450%, $900M Due 2035 At 5.200%, And $500M Due 2055 At 5.950%
➖ NeutralBenzinga•Sep 3, 2025, 06:49 AM
Royalty Pharma To Provide Up To $300M In Funding To Zenas BioPharma In Exchange For Royalty On Sales Of Obexelimab
📈 PositiveBenzinga•Sep 2, 2025, 11:10 AM•Also:
BeOne Medicines shares are trading higher after the company agreed to sell royalty rights on Amgen's IMDELLTRA sales outside China to Royalty Pharma for up to $950 million.
📈 PositiveBenzinga•Aug 25, 2025, 11:47 AM•Also: ,
BeOne Medicines Agrees To Sell Its Royalty Rights On The Worldwide Sales, Excluding China, Of Amgen's Imdelltra (Tarlatamab-dlle) For Up To $950M To Royalty Pharma
📈 PositiveBenzinga•Aug 25, 2025, 10:07 AM•Also: ,
Frequently Asked Questions about RPRX
What is RPRX's current stock price?
Royalty Pharma plc (RPRX) is currently trading at $38.60 per share. The stock has moved +0.44% today.
What is the analyst price target for RPRX?
The average analyst price target for RPRX is $43.50, based on 1 analyst.
What sector is Royalty Pharma plc in?
Royalty Pharma plc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is RPRX's market cap?
Royalty Pharma plc has a market capitalization of $16.76 billion, making it a large-cap company.
Does RPRX pay dividends?
No, Royalty Pharma plc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorEXEL
Exelixis, Inc.
$44.30
Mkt Cap: $11.9B
FMS
Fresenius Medical Care AG & Co. KGaA
$23.51
Mkt Cap: $13.8B
GMAB
Genmab A/S
$32.38
Mkt Cap: $19.9B
HOLX
Hologic, Inc.
$74.95
Mkt Cap: $16.7B
INCY
Incyte Corporation
$102.69
Mkt Cap: $20.2B
ROIV
Roivant Sciences Ltd.
$22.41
Mkt Cap: $15.6B
SMMT
Summit Therapeutics Inc.
$17.82
Mkt Cap: $13.3B
SNN
Smith & Nephew plc
$32.82
Mkt Cap: $14.4B
THC
Tenet Healthcare Corporation
$196.33
Mkt Cap: $17.3B
UTHR
United Therapeutics Corporation
$517.13
Mkt Cap: $23.1B
Explore stocks similar to RPRX for comparison